NASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis $588.34 -8.51 (-1.43%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$591.22 +2.88 (+0.49%) As of 05/23/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Regeneron Pharmaceuticals Stock (NASDAQ:REGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get REGN alerts:Sign Up Key Stats Today's Range$582.37▼$591.6450-Day Range$527.78▼$672.3652-Week Range$520.50▼$1,211.20Volume655,734 shsAverage Volume799,208 shsMarket Capitalization$63.52 billionP/E Ratio15.37Dividend Yield0.60%Price Target$890.60Consensus RatingModerate Buy Company OverviewRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More… Regeneron Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreREGN MarketRank™: Regeneron Pharmaceuticals scored higher than 96% of companies evaluated by MarketBeat, and ranked 51st out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 19 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth5.85% Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 5.85% in the coming year, from $35.92 to $38.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 15.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 15.37, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.72.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.34. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Regeneron Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.78% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 11.15%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRegeneron Pharmaceuticals has a dividend yield of 0.15%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Regeneron Pharmaceuticals is 8.96%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Regeneron Pharmaceuticals will have a dividend payout ratio of 9.26% next year. This indicates that Regeneron Pharmaceuticals will be able to sustain or increase its dividend.Read more about Regeneron Pharmaceuticals' dividend. Sustainability and ESG2.3 / 5Environmental Score-2.69 Percentage of Shares Shorted2.78% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 11.15%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment1.02 News SentimentRegeneron Pharmaceuticals has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 60 news articles for Regeneron Pharmaceuticals this week, compared to 30 articles on an average week.Search Interest38 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 65% compared to the previous 30 days.MarketBeat FollowsOnly 13 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -19% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.02% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Stock News HeadlinesBig Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025 (REGN)CCOI, AESI, and REGN are near one-year lows but remain favored by analysts; watch these stocks for future growth potential.May 15, 2025 | marketbeat.comBest Biotech Stocks to Buy in 2025 (REGN)Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.May 13, 2025 | marketbeat.comMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millions of years. And both grizzled oilmen and clean energy supporters love it: Energy Secretary Chris Wright called it "an awesome resource," while Warren Buffett, Jeff Bezos, Mark Zuckerberg, and Bill Gates are all directly invested.May 24, 2025 | Stansberry Research (Ad)Regeneron Pharmaceuticals Presents Promising Initial Results from LINKER-MM2 Trial of Linvoseltamab Combinations for Relapsed/Refractory Multiple Myeloma at ASCO 2025May 22 at 5:28 PM | quiverquant.comLinvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple MyelomaMay 22 at 5:00 PM | globenewswire.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Made A “Very Smart Deal,” Says Jim CramerMay 22 at 10:54 AM | insidermonkey.comRegeneron buying 23andMe; What happened to 23andMe? Should I delete 23andMe data?May 22 at 9:01 AM | msn.comRegeneron to buy bankrupt 23andMe, vows ethical use of customer DNA dataMay 21 at 10:59 PM | msn.comSee More Headlines REGN Stock Analysis - Frequently Asked Questions How have REGN shares performed this year? Regeneron Pharmaceuticals' stock was trading at $712.33 at the beginning of the year. Since then, REGN stock has decreased by 17.4% and is now trading at $588.34. View the best growth stocks for 2025 here. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its quarterly earnings data on Tuesday, April, 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by $0.61. The firm's quarterly revenue was down 3.7% compared to the same quarter last year. Read the conference call transcript. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiaries of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and more. Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' top institutional investors include Vanguard Group Inc. (8.61%), Dodge & Cox (2.13%), Price T Rowe Associates Inc. MD (1.99%) and Amundi (1.47%). Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Neil Stahl, Andrew J Murphy, Joseph J Larosa, Robert E Landry, Plew Daniel P Van, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Jason Pitofsky, Marc Tessier-Lavigne, Christine A Poon, Michael S Brown, Bonnie L Bassler, Huda Y Zoghbi and N Anthony Coles. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Record date for 3/20 Dividend2/20/2025Ex-Dividend for 3/20 Dividend2/20/2025Dividend Payable3/20/2025Last Earnings4/29/2025Record date for 6/6 Dividend5/20/2025Ex-Dividend for 6/6 Dividend5/20/2025Today5/23/2025Dividend Payable6/06/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees11,900Year Founded1988Price Target and Rating Average Stock Price Target$890.60 High Stock Price Target$1,200.00 Low Stock Price Target$150.00 Potential Upside/Downside+51.4%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage26 Analysts Profitability EPS (Most Recent Fiscal Year)$39.28 Trailing P/E Ratio15.37 Forward P/E Ratio16.38 P/E Growth2.34Net Income$4.41 billion Net Margins31.07% Pretax Margin33.66% Return on Equity16.32% Return on Assets12.76% Debt Debt-to-Equity Ratio0.09 Current Ratio4.73 Quick Ratio3.95 Sales & Book Value Annual Sales$14.09 billion Price / Sales4.51 Cash Flow$38.63 per share Price / Cash Flow15.23 Book Value$268.50 per share Price / Book2.19Miscellaneous Outstanding Shares107,965,000Free Float101,147,000Market Cap$63.52 billion OptionableOptionable Beta0.43 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:REGN) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredThe “black glass” breakthrough behind AI’s next leapAI is advancing fast… But there’s one problem almost no one’s talking about. Power.True Market Insiders | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.